FDA will approve daraxonrasib for RAS cancers

The FDA will approve Revolution Medicines' daraxonrasib, clearing the oral RAS inhibitor for RAS-mutated cancers. The agency accepted Revolution's NDA on July 22 and the company opened expanded access after a 'safe-to-proceed' letter on April 30, and over 2,000 patients are already receiving daraxo…